Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials - investor.lilly.com
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
Comments